Yin Ling, Wang Xue-Jing, Chen De-Xi, Liu Xiao-Ni, Wang Xiao-Jun
Department of Integrated Traditional Chinese and Western Medicine, Beijing Youan Hospital, Capital Medical University Beijing, China.
Beijing Institute of Hepatology, Beijing Youan Hospital, Capital Medical University Beijing, China.
Am J Cancer Res. 2020 Dec 1;10(12):4568-4584. eCollection 2020.
Due to the refractory and partial sensitive treatments to malignant cancers, immunotherapy has increasingly become a hotspot in effective anti-tumor research. However, at present, existing animal models could not accurately describe the interaction between human tissue and tumor cells for preclinical trials. Furthermore, it is a tough obstacle to reconstitute the immune system and microenvironment in a mouse model identical to humans due to species differences. In the establishment of the humanized mouse model, the co-transplantation of human immunocytes with/without tissues and tumor cells is the key breakthrough to solve this problem. The compelling progress has been investigated in the preclinical drug test for diverse tumor types. This review mainly summarized the development of immunodeficient mice, and the construction and practicability of the humanized mouse model. Furthermore, the investigators also highlight the pros and cons, and recent progress in immunotherapy research for advanced utility of human cancer diseases.
由于恶性癌症治疗存在难治性且部分治疗敏感,免疫疗法日益成为有效抗肿瘤研究的热点。然而,目前现有的动物模型无法准确描述人体组织与肿瘤细胞在临床前试验中的相互作用。此外,由于物种差异,在与人类相同的小鼠模型中重建免疫系统和微环境是一个艰巨的障碍。在人源化小鼠模型的建立中,将人免疫细胞与组织和肿瘤细胞一起或不与它们一起共同移植是解决这一问题的关键突破。在针对多种肿瘤类型的临床前药物测试中已取得了令人瞩目的进展。本综述主要总结了免疫缺陷小鼠的发展,以及人源化小鼠模型的构建和实用性。此外,研究者还强调了其优缺点,以及在人类癌症疾病高级应用的免疫疗法研究中的最新进展。